Patents Assigned to Molecular Diagnostics, Inc.
  • Patent number: 10392670
    Abstract: Compositions, reactions mixtures, kits, and systems for detecting bacterial contamination are provided, as well as methods of using the same.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: August 27, 2019
    Assignee: DCH MOLECULAR DIAGNOSTICS, INC.
    Inventors: James Jian Quan Wang, Xiangmin Cui, HiuNam Chan
  • Publication number: 20190226013
    Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.
    Type: Application
    Filed: April 8, 2019
    Publication date: July 25, 2019
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce A. Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
  • Patent number: 10294515
    Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes, and detecting the fusion probe after nuclease treatment. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes, and detecting these probes after nuclease treatment. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: May 21, 2019
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
  • Publication number: 20190017112
    Abstract: The present disclosure provides methods and kits for direct sequencing of nucleic acid targets. Such methods can be used to determine if one or more nucleic acid targets are present in a sample.
    Type: Application
    Filed: February 10, 2017
    Publication date: January 17, 2019
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Debrah Thompson, Matthew Rounseville
  • Publication number: 20180340231
    Abstract: Described herein are innovations for classifying subtypes of DLBCL, as well as using the results of classification for diagnosis, prognosis, and therapy selection. In this way, the classifier can effectively classify subtypes of DLBCL and provide meaningful output for the benefit of medical practices and DLBCL patients. Also described are arrays and kits that can be used to measure expression of DLBCL signatures genes.
    Type: Application
    Filed: September 29, 2016
    Publication date: November 29, 2018
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Bonnie LaFleur, Qian Liu, John W. Luecke, Patrick C. Roche
  • Patent number: 9765385
    Abstract: Disclosed herein are methods for detecting presence of a nucleotide variant in a target nucleic acid utilizing a nuclease protection assay. The methods include contacting a sample with at least two probes, wherein the first probe is complementary to the wild-type (non-variant) nucleotide(s) at the nucleotide variant position(s) in the target nucleic acid and the second probe is complementary to the variant nucleotide(s) at the nucleotide variant position(s) in the target nucleic acid, under conditions sufficient for the probes to hybridize to the target nucleic acid, producing a mixture of hybridized and unhybridized nucleic acids. The mixture is contacted with a nuclease specific for single-stranded nucleic acid molecules under conditions sufficient to remove unhybridized nucleic acid molecules (or unhybridized portions of nucleic acid molecules). The presence of the at least two probes is then detected, thereby detecting the presence of the variant and/or non-variant target nucleic acid in the sample.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: September 19, 2017
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Matt Rounseville, Bruce Seligmann
  • Patent number: 9758829
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: September 12, 2017
    Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
  • Patent number: 9512469
    Abstract: Disclosed herein are methods of co-detecting presence of target messenger RNA (mRNA) and small non-coding RNA (for example, miRNA) in a sample. The disclosed methods can be used to simultaneously detect mRNA and small non-coding RNA in a single assay (for example in the same reaction or the same well of a multi-well assay). The methods can include contacting a sample with a plurality of nuclease protection probes (NPPs) including at least one probe which specifically binds to a target mRNA and at least one probe which specifically binds to a target small non-coding RNA, contacting the sample with a nuclease specific for single-stranded nucleic acids, and detecting the NPP, for example on a microarray.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: December 6, 2016
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce Seligmann, Matt Rounseville, Krishna Maddula, Ihab Botros, Chris Cox
  • Publication number: 20160019337
    Abstract: This disclosure concerns the identification of biomarkers that are characteristic of squamous or non squamous (e.g., adenocarcinoma, large cell carcinoma, carcinoid tumor, sarcomatoid carcinoma) subtypes of non small cell lung cancer (NSCLC), clinically useful NSCLC classifiers, kits and arrays for distinguishing squamous and nonsquamous NSCLC subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing.
    Type: Application
    Filed: March 3, 2014
    Publication date: January 21, 2016
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Christopher Roberts, Hui Wang, Zhenquiang Lu, Krishna Maddula, Sam Rua, Kevin Knapp, Byron Lawson, Debrah Thompson, Michael Hrubiak, Tyler Breedlove, Vijay Modur
  • Publication number: 20150176072
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Application
    Filed: June 24, 2013
    Publication date: June 25, 2015
    Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon
  • Publication number: 20140235460
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 21, 2014
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Debrah Thompson, Bruce E. Seligmann, Debra A. Gordon
  • Patent number: 8741564
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: June 3, 2014
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon
  • Publication number: 20140120540
    Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes, and detecting the fusion probe after nuclease treatment. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes, and detecting these probes after nuclease treatment. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.
    Type: Application
    Filed: December 7, 2011
    Publication date: May 1, 2014
    Applicant: HTG MOLECULAR DIAGNOSTICS, INC.
    Inventors: Bruce Seligmann, Bj Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
  • Publication number: 20140087954
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Application
    Filed: April 26, 2012
    Publication date: March 27, 2014
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce E. Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon
  • Patent number: 8624014
    Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: January 7, 2014
    Assignee: Luminex Molecular Diagnostics, Inc.
    Inventors: Daniel Kobler, Daniel Fieldhouse
  • Publication number: 20130288915
    Abstract: Disclosed herein are methods of predicting response of a tumor to an ALK inhibitor and methods of determining diagnosis or prognosis of a subject with a tumor. The methods can include detecting presence of an ALK gene fusion (such as EML4-ALK, TFG-ALK, or KIF5B-ALK) in a sample from a subject. Also disclosed herein are arrays for detecting the presence of ALK and/or ROS1 gene fusions in a sample. In some embodiments, the array includes one or more oligonucleotides complementary to an ALK or ROS1 gene fusion.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 31, 2013
    Applicant: HTG MOLECULAR DIAGNOSTICS, INC.
    Inventors: BRUCE E. SELIGMANN, BJ KERNS, MARK SCHWARTZ, JOHN W. LUECKE
  • Patent number: 8338579
    Abstract: The present invention provides novel binding pair compositions of defined and limited stability comprising nucleic acid detection markers useful for the homogeneous, sensitive detection of analytes. Also provided are methods for the sensitive homogeneous detection of analytes, particularly analytes of clinical relevance. Kits for preparing binding pairs of the invention and for performing the methods of the invention are also provided.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: December 25, 2012
    Assignee: Iris Molecular Diagnostics, Inc.
    Inventors: Thomas Adams, Edward Jablonski
  • Patent number: 7960537
    Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: June 14, 2011
    Assignee: Luminex Molecular Diagnostics, Inc.
    Inventors: Petr Pancoska, Vit Janota, Albert S. Benight, Richard S. Bullock, Peter V. Riccelli, Daniel Kobler, Daniel Fieldhouse
  • Patent number: 7943322
    Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24 mers is described.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: May 17, 2011
    Assignee: Luminex Molecular Diagnostics, Inc.
    Inventors: Petr Pancoska, Vit Janota, Albert S. Benight, Richard S. Bullock, Peter V. Riccelli, Daniel Kobler, Daniel Fieldhouse
  • Patent number: 7927809
    Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: April 19, 2011
    Assignee: Luminex Molecular Diagnostics, Inc.
    Inventors: Petr Pancoska, Vit Janota, Albert S. Benight, Richard S. Bullock, Peter V. Riccelli, Daniel Kobler, Daniel Fieldhouse